# OnCo record b-drug-pricing (bottleneck). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/bottlenecks/b-drug-pricing/>
  a schema:Thing ;
  onco:kind "bottleneck" ;
  schema:identifier "b-drug-pricing" ;
  schema:name "Prices and value"@en ;
  schema:description "New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt."@en ;
  schema:url <https://onco.cc/bottlenecks/b-drug-pricing/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/nrclinonc.2017.31>, <https://doi.org/10.1016/S1470-2045(20)30139-X>, <https://doi.org/10.1377/hlthaff.2012.1263>, <https://www.cms.gov/inflation-reduction-act-and-medicare/medicare-drug-price-negotiation> ;
  onco:related <https://onco.cc/collections/fda-approvals/>, <https://onco.cc/collections/esmo-guidelines/>, <https://onco.cc/collections/nccn/>, <https://onco.cc/ideas/idea-reg-io-subscription-national/>, <https://onco.cc/ideas/idea-reg-indication-specific-pricing/>, <https://onco.cc/ideas/idea-reg-pooled-procurement-adult-essentials/>, <https://onco.cc/ideas/idea-reg-biosimilar-no-efficacy-trial/>, <https://onco.cc/ideas/idea-reg-pd1-biosimilar-advance-commitment/>, <https://onco.cc/ideas/idea-reg-patent-pool-oncology-eml/>, <https://onco.cc/ideas/idea-reg-price-anchored-to-mcbs/>, <https://onco.cc/ideas/idea-reg-weight-based-io-dosing-label/>, <https://onco.cc/ideas/idea-reg-public-deescalation-trials-for-cost/>, <https://onco.cc/ideas/idea-reg-financial-toxicity-vital-sign/>, <https://onco.cc/ideas/idea-reg-net-price-transparency-registry/>, <https://onco.cc/ideas/idea-reg-rd-cost-disclosure-condition/>, <https://onco.cc/ideas/idea-reg-provisional-price-until-os/>, <https://onco.cc/ideas/idea-reg-patent-buyout-prize/>, <https://onco.cc/ideas/idea-reg-secondary-patent-thicket-limits/>, <https://onco.cc/ideas/idea-reg-nonprofit-generic-chemo-manufacturer/>, <https://onco.cc/ideas/idea-reg-academic-cart-at-cost-coverage/>, <https://onco.cc/ideas/idea-reg-combination-price-attribution/>, <https://onco.cc/ideas/idea-reg-middle-income-negotiation-bloc/>, <https://onco.cc/ideas/idea-reg-tiered-pricing-for-exclusivity/>, <https://onco.cc/ideas/idea-reg-biosimilar-first-default-switching/>, <https://onco.cc/ideas/idea-reg-annuity-payment-durable-therapies/>, <https://onco.cc/ideas/idea-reg-social-impact-bond-switching/>, <https://onco.cc/ideas/idea-reg-market-expansion-repricing/>, <https://onco.cc/ideas/idea-moon-pay-for-cure-contracts/>, <https://onco.cc/ideas/idea-moon-neoantigen-vaccines-at-scale/>, <https://onco.cc/ideas/idea-cost-asp-flat-fee/>, <https://onco.cc/ideas/idea-cost-site-neutral-infusion/>, <https://onco.cc/ideas/idea-cost-340b-pass-through/>, <https://onco.cc/ideas/idea-cost-indication-based-pricing/>, <https://onco.cc/ideas/idea-cost-inflation-rebates-commercial/>, <https://onco.cc/ideas/idea-cost-part-b-cap/>, <https://onco.cc/ideas/idea-cost-biosimilar-default-substitution/>, <https://onco.cc/ideas/idea-cost-interchangeable-oncology-biosimilars/>, <https://onco.cc/ideas/idea-cost-nonprofit-generic-oncology/>, <https://onco.cc/ideas/idea-cost-transparent-generic-pricing/>, <https://onco.cc/ideas/idea-cost-vial-sharing-dose-rounding/>, <https://onco.cc/ideas/idea-cost-federal-oral-parity/>, <https://onco.cc/ideas/idea-cost-value-scale-in-coverage/>, <https://onco.cc/ideas/idea-cost-managed-access-everywhere/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/adc/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-biosimilars/>, <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/tisagenlecleucel/> ;
  onco:institutions <https://onco.cc/institutions/esmo/>, <https://onco.cc/institutions/asco/>, <https://onco.cc/institutions/nccn-org/> ;
  onco:terms <https://onco.cc/terms/biosimilar/>, <https://onco.cc/terms/accelerated-approval/>, <https://onco.cc/terms/real-world-evidence/>, <https://onco.cc/terms/standard-of-care/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-prasad-nat-rev-clin-oncol/>, <https://onco.cc/key-papers/paper-vokinger-lancet-oncol/>, <https://onco.cc/key-papers/paper-ramsey-health-aff-millwood/> .